« Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill », Can IBD Today, vol. 1, nᵒ S11, p. 2–11, nov. 2023, doi: 10.58931/cibdt.2023.1S1121.